ICU MEDICAL INC/DEICUI
ICU MEDICAL INC/DE Revenue Disclosure
REVENUE
Revenue Recognition
Our business units are Consumables, Infusion Systems and Vital Care. The vast majority of our sales of these products within these business units are made on a stand-alone basis to hospitals and distributors. Revenue is typically recognized upon transfer of control of the products, which we deem to be at point of shipment. For purposes of revenue recognition for our
software licenses and renewals, we consider the control of these products to be transferred to a customer at a certain point in time; therefore, we recognize revenue at the start of the applicable license term.
Payment is typically due in full within 30 days of delivery or the start of the contract term. Revenue is recorded in an amount that reflects the consideration we expect to be entitled to in exchange for those goods or services. We include variable consideration in net sales only to the extent that a significant reversal in revenue is not probable when the uncertainty is resolved. Our variable consideration includes distributor chargebacks, product returns and end customer rebates with distributor chargebacks representing the majority and subject to the greatest judgment (see Note 1: Basis of Presentation and Significant Accounting Policies).
We also offer certain volume-based rebates to both our distribution and end customers, which is recorded as variable consideration when calculating the transaction price. Rebates are offered on both a fixed and tiered/variable basis. In both cases, we use information available at the time, including current contractual requirements, our historical experience with each customer and forecasted customer purchasing patterns, to estimate the most likely rebate amount. We also warrant products against defects and have a policy permitting the return of defective products. We also provide for extended service-type warranties, which we consider to be separate performance obligations. We allocate a portion of the transaction price to the extended service-type warranty based on its estimated relative selling price, and recognize revenue over the period the warranty service is provided. See Note 1: Basis of Presentation and Significant Accounting Policies for further discussion.
Arrangements with Multiple Performance Obligations
We also enter into arrangements which include multiple performance obligations, (see Note 1: Basis of Presentation and Summary of Significant Accounting Policies). The most significant judgments related to these arrangements include:
•Identifying the various performance obligations of these arrangements.
•Estimating the relative standalone selling price of each performance obligation, typically using a directly observable method or calculated on a cost plus margin basis method.
Revenue disaggregated
The following table represents our revenues disaggregated by product line (in thousands) and our disaggregated product line revenue as a percentage of total revenue:
| Year ended December 31, | |||||||||||||||||||||||||||||||||||
| 2025 | 2024 | 2023 | |||||||||||||||||||||||||||||||||
| Product line | Revenue | % of Revenue | Revenue | % of Revenue | Revenue | % of Revenue | |||||||||||||||||||||||||||||
| Consumables | $ | 1,109,130 | 50 | % | $ | 1,038,869 | 44 | % | $ | 969,129 | 43 | % | |||||||||||||||||||||||
| Infusion Systems | 684,208 | 31 | % | 652,410 | 27 | % | 629,043 | 28 | % | ||||||||||||||||||||||||||
| Vital Care | 437,924 | 19 | % | 690,767 | 29 | % | 660,954 | 29 | % | ||||||||||||||||||||||||||
| Total Revenues | $ | 2,231,262 | 100 | % | $ | 2,382,046 | 100 | % | $ | 2,259,126 | 100 | % | |||||||||||||||||||||||
We report revenue on a "where sold" basis, which reflects the revenue within the country or region in which the ultimate sale is made to our external customer.
The following table represents our revenues disaggregated by geography (in thousands):
| Year ended December 31, | |||||||||||||||||
| Geography | 2025 | 2024 | 2023 | ||||||||||||||
| United States | $ | 1,356,114 | $ | 1,532,104 | $ | 1,440,017 | |||||||||||
| Europe, the Middle East and Africa | 411,684 | 393,530 | 373,571 | ||||||||||||||
| Asia-Pacific | 232,903 | 232,820 | 241,699 | ||||||||||||||
| Other Foreign | 230,561 | 223,592 | 203,839 | ||||||||||||||
| Total Revenues | $ | 2,231,262 | $ | 2,382,046 | $ | 2,259,126 | |||||||||||
Domestic sales accounted for 61%, 64% and 64% of total revenue in 2025, 2024 and 2023, respectively. International sales accounted for 39%, 36% and 36% of total revenue in 2025, 2024 and 2023, respectively.
Contract balances
Our contract balances (deferred revenue) are recorded in accrued liabilities and other long-term liabilities in our consolidated balance sheet (see Note 11: Accrued Liabilities). The following table presents the changes in our contract balances for the years ended December 31, 2024 and 2023, (in thousands):
| Contract Liabilities | |||||
| Beginning balance, January 1, 2024 | $ | 42,177 | |||
| Equipment revenue recognized | (56,182) | ||||
| Equipment revenue deferred due to implementation | 55,932 | ||||
| Software revenue recognized | (28,292) | ||||
| Software revenue deferred due to implementation | 29,913 | ||||
Government grant income recognized(1) | (2,072) | ||||
| Government grant income deferred | — | ||||
| Other deferred revenue recognized | (2,576) | ||||
| Other deferred revenue | 503 | ||||
| Ending balance, December 31, 2024 | 39,403 | ||||
| Equipment revenue recognized | (65,792) | ||||
| Equipment revenue deferred due to implementation | 74,836 | ||||
| Software revenue recognized | (35,715) | ||||
| Software revenue deferred due to implementation | 31,373 | ||||
Government grant income recognized(1) | (2,066) | ||||
| Government grant income deferred | — | ||||
| Other deferred revenue recognized | (1,983) | ||||
| Other deferred revenue | 1,177 | ||||
| Ending balance, December 31, 2025 | $ | 41,233 | |||
____________________________
(1) The government grant income deferred is amortized over the life of the related depreciable asset as a reduction to depreciation expense.
During 2025, we recognized $35.5 million in revenue that was included in the opening contract balances as of December 31, 2024.
As of December 31, 2025, revenue from remaining performance obligations is as follows (in thousands):
| Recognition Timing | |||||||||||
| <12 Months | > 12 Months | ||||||||||
| Equipment revenue | $ | 24,530 | $ | 372 | |||||||
| Software revenue | 6,361 | 1,719 | |||||||||
Government grant deferred income(1) | 2,064 | 5,277 | |||||||||
Other deferred revenue(2) | 888 | 22 | |||||||||
| Total | $ | 33,843 | $ | 7,390 | |||||||
____________________________
(1) The government grant deferred income is amortized over the life of the related depreciable asset as a reduction to depreciation expense.
(2) Other deferred revenue includes pump development programs, purchased training and extended warranty.
Costs to Obtain a Contract with a Customer
As part of the cost to obtain a contract, we may pay incremental commissions to sales employees upon entering into a sales contract. Under ASC Topic 606, we have elected to expense these costs as incurred as the period of benefit is less than one year.
Practical expedients and exemptions
In addition to the practical expedient applied to sales commissions, under ASC Topic 606, we elected to apply the practical expedient for shipping and handling costs incurred after the customer has obtained control of a good. We will continue to treat these costs as a fulfillment cost rather than as an additional promised service.
Historical Timeline
| Fiscal Year | Filed | |
|---|---|---|
| 2025 | Feb 19, 2026 | Showing above |
| 2024 | Feb 27, 2025 | |
| 2023 | Feb 27, 2024 | |
| 2022 | Feb 27, 2023 | |
| 2021 | Feb 25, 2022 | |
About Revenue Disclosures
Revenue disclosures under ASC 606 explain how a company identifies performance obligations, allocates transaction prices, and determines when revenue is recognized. This section is essential for understanding whether reported revenue reflects genuine economic activity or aggressive accounting choices. Analysts examine the mix of point-in-time versus over-time recognition, which directly affects revenue timing and comparability.
Key signals: rising contract liabilities (deferred revenue) suggest strong future revenue visibility, while declining contract assets may indicate slowing project milestones. Watch for variable consideration estimates — rebates, returns, and performance bonuses that require management judgment. Significant changes in disaggregated revenue by geography or product line can reveal shifting business mix before it appears in headline numbers. Compare revenue growth against contract liability growth to assess sustainability, and scrutinize any changes in the timing of recognition that coincide with earnings pressure.